New Dimensions in Vascular Engineering: Opportunities for Cancer Biology

Sina Y. Rabbany, Ph.D.,^{1,2} Daylon James, Ph.D.,¹ and Shahin Rafii, M.D.¹

Angiogenesis is a fundamental prerequisite for tissue growth and thus an attractive target for cancer therapeutics. However, current efforts to halt tumor growth using antiangiogenic agents have been met with limited success. A reason for this may be that studies aimed at understanding tissue and organ formation have to this point utilized two-dimensional cell culture techniques, which fail to faithfully mimic the pathological architecture of disease in an *in vivo* context. In this issue of *Tissue Engineering*, the work of Fischbach-Teschl's group manipulate such variables as oxygen concentration, culture three-dimensionality, and cell–extracellular matrix interactions to more closely approximate the biophysical and biochemical microenvironment of tumor angiogenesis. In this article, we discuss how novel tissue engineering platforms provide a framework for the study of tumorigenesis under pathophysiologically relevant *in vitro* culture conditions.

ANGIOGENESIS IS A critical step in cancer development, whereby tumors establish dedicated blood vessels to facilitate growth, invasion, and metastasis.¹ This complex and highly regulated process, which involves the migration and proliferation of endothelial cells (ECs), is driven by tumor-cell-derived pro-angiogenic signals, yielding continued tumor growth and metastasis. Once a tumor acquires a dedicated blood supply, it facilitates growth and spread of cancer cells to other organs. Additional studies confirm that malignant transformation is associated with the upregulation of tumor-specific factors that selectively induce the assembly of tumor vessels.² Several studies have suggested that angiogenesis is in fact the rate-limiting step in tumor growth and progression.^{3,4} Recently, the idea was introduced that ECs do not only function as the passive building blocks of blood vessels, but also comprise a vascular niche that nurtures tumor growth and initiates tissue regeneration directly through elaboration of specific growth factors.⁵

Normal blood vessels and tumor-induced blood vessels differ greatly in morphology and function. Normal neoangiogenic vessels recruit pericytes and vascular smooth muscle cells to the ECs to stabilize these vessels.⁶ By contrast, tumor-induced blood vessels are often less stable, disorganized, and leaky. They lack a hierarchical arrangement, have irregular diameters, and follow random branching patterns. Tumor growth in tissues leads to increasing hydrostatic and solid pressures, inducing tumor cell quiescence and necrosis, as well as blood vessel collapse.

Current efforts in regenerative medicine aimed at recreating the unique microenvironments surrounding both normal and tumor-driven neoangiogenesis have been met with limited success. The principal difficulty stems from the lack of a physiological reproduction of growth factor gradients, which are critical to create a pro-angiogenic niche. Traditional static two-dimensional cell culture systems reduce the biological relevance and complexity of dynamic tissue architectures. For these reasons, three-dimensional (3D) tissue constructs better reflect native biophysical and biochemical environments, and hence have become a focus of recent investigations.⁷

The complexity of angiogenesis suggests the existence of multiple controls, some of which may be better evaluated with bioengineering approaches. To improve the angiogenic capability of engineered tissues, design of scaffolds provides a spatio-temporally controlled delivery of cells and/or growth factors in both *in vitro* and *in vivo* models. To create a microenvironment that more accurately mimics a tumor microenvironment, 3D models have been engineered to recreate the *in vivo* tumor niche by growing cells in polymeric scaffolds.^{8,9}

In this issue, Fischbach-Teschl and colleagues,¹⁰ in their article titled "Oxygen-Controlled 3D Cultures to Analyze Tumor Angiogenesis," report on a 3D microscale tumor model to define the distinct importance of oxygen concentration, culture dimensionality, and cell–extracellular matrix interactions on the angiogenic capability of carcinoma cells.

¹Department of Genetic Medicine, Weill Cornell Medical College, Howard Hughes Medical Institute, New York, New York.

²Bioengineering Program, Hofstra University, Hempstead, New York.

Their studies were focused on defining the distinct roles of oxygen and 3D cell–extracellular matrix interactions in pathologically relevant culture conditions *in vitro*. Such systems are aimed at modulating the angiogenic potential of tumor cells, and hence improving our understanding of tumor angiogenesis.

Malignant transformation occurs within the context of a dynamically evolving stroma in three dimensions. In contrast to normal healthy tissues, the vasculature of solid tumors has a limited reach, resulting in pockets of low oxygen concentration. This causes the tumor's hypoxic core to become necrotic, with a surrounding layer of cells whose exposure to hypoxia triggers a cascade of hypoxia-inducible factor-1 and vascular-endothelial-growth-factor-mediated signaling events that initiate tumor neovascularization. Three-dimensional cultures may be utilized to study the mechanisms of cancer cell signaling in this distinctive tumor hypoxic microenvironment. We have recently succeeded in generating stable cocultures of vascular cells in a honeycomb alginate scaffold (with an average channel diameter of 300 μm) that can self-organize into capillary-like structures. The porous 3D alginate depots containing the cells, in a serum-free condition, were further exposed to laminar flow to recapitulate the vasculature *in vivo*. The scaffold remained intact with the cells remaining adhered to it and aligned in the direction of flow, demonstrating its suitability for establishing durable angiogenic modules that may ultimately enhance organ revascularization or model tumor neoangiogenesis.¹¹

A major unresolved issue concerning the investigation of interaction of cancer cells with endothelium is the requirement for a source of viable, stable ECs *in vitro*. The ability of human embryonic stem cells (hESCs) to self-renew and to generate ECs for therapeutic revascularization has also been recently demonstrated. hESCs, in addition to their self-renewal capacity, have the potential for large-scale differentiation into any adult cell type *in vitro*,¹² and are thus an attractive alternative source of ECs. The emergence of ECs from differentiating hESCs in real time was monitored by an EC-specific genetic reporter, whereby the vascular endothelial cadherin (VE-Cad) promoter drives expression of green fluorescent protein (hVPr-GFP).¹³ This novel approach for vascular monitoring in combination with the ability to grow cells on 3D platforms will allow for closer scrutiny of tumor growth while examining the contribution of the hVPr-GFP+ ECs to the neoangiogenic process.

Additionally, biologically compatible scaffolds enable *in-vitro*-generated vascular cells to receive and respond to important mechanical stimuli in three dimensions.

Mechanical signals regulate multiple cellular processes and thus have numerous effects on tissue development (including blood vessels) and in disease processes. Such stimuli, such as hemodynamic shear stress, influence the cytoskeleton assembly directly, thereby translating the mechanical signal into changes in biochemical signaling pathways (i.e., mechanotransduction). It is therefore important to elucidate cellular mechanochemical interactions in 3D to improve engineered tissue models and to better investigate these processes *in vivo*.

Some may argue that 3D cultures fail to accurately reproduce the complexity of tumor cell biology *in vivo*. However, if cell cultures in three dimensions increase the survival and/or the expansion of cancer cells from solid tumors, they may offer utility in the preclinical analyses of the molecular

mechanisms underlying tumor biology. In summary, biomaterials are used in a variety of tissue engineering and drug delivery projects to promote angiogenesis, and hence influence the regeneration of tissues and organs in the body. Such approaches will enable us to grow, or engineer, long-lasting tissues and organs using 3D depots, which may serve to guide new tissue formation therapeutically in the body or *in vitro* as physiological models to study disease pathogenesis.

Insights gained from 3D platforms may improve our understanding of cancer and contribute to the development of antiangiogenic therapies. Can tissue engineering transform the cancer field by providing innovative tools to study tumorigenesis under pathologically relevant culture conditions? This is a question that only time and intensive investigation can answer.

Acknowledgments

The work is supported by grants from Howard Hughes Medical Institute, Ansary Stem Cell Institute, National Heart, Lung, and Blood Institute R01 Grants HL075234 and HL097797, New York Stem Cell Foundation, Empire State Stem Cell Board, and New York State Department of Health, NYS C024180. We thank Edo Israely for his critical review of the article.

Disclosure Statement

No competing financial interests exist.

References

1. Folkman, J. Tumor angiogenesis: therapeutic implications. *N Engl J Med* **285**, 1182, 1971.
2. Hanahan, D., and Folkman, J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. *J Cell* **86**, 353, 1996.
3. Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease. *Nat Med* **1**, 27, 1995.
4. Bergers, G., and Benjamin, L.E. Tumorigenesis and the angiogenic switch. *Nat Rev Cancer* **3**, 401, 2003.
5. Butler, J., Kobayashi, H., and Rafii, S. Instructive role of the vascular niche in promoting tumour growth and tissue repair by angiocrine factors. *Nat Rev Cancer* **10**, 138, 2010.
6. Carmeliet, P. Angiogenesis in health and disease. *Nat Med* **9**, 653, 2003.
7. Yamada, K.M., and Cukierman, E. Modeling tissue morphogenesis and cancer in 3-D. *Cell* **130**, 601, 2007.
8. Fischbach, C., Chen, R., Matsumoto, T., Schmelzle, T., Brugge, J.S., Polverini, P.J., and Mooney, D.J. Engineering tumors with 3D scaffolds. *Nat Methods* **4**, 855, 2007.
9. Brekhan, V., and Neufeld, G. A novel asymmetric 3D *in-vitro* assay for the study of tumor cell invasion. *BMC Cancer* **9**, 415, 2009.
10. Verbridge, S.S., Choi, N.W., Zheng, Y., Brooks, D.J., Stroock, A.D., Fischbach, C. *Tissue Eng* 2010.
11. Yamamoto, M., James, D., Li, H., Butler, J., Rafii, S., and Rabbany, S. Generation of stable co-cultures of vascular cells in a honeycomb alginate scaffold. *Tissue Eng Part A* **16**, 299, 2010.
12. Thomson, J.A., Itskovitz-Eldor, J., Shapiro, S.S., Waknitz, M.A., Swiergel, J.J., Marshall, V.S., and Jones, J.M. Embryonic stem cell lines derived from human blastocysts. *Science* **282**, 1145, 1998.

13. James, D., Nam, H., Seandel, M., Nolan, B., Janovitz, T., Tomishima, M., Studer, L., Lee, G., Lyden, D., Benezra, R., Zaninovic, N., Rosenwaks, Z., Rabbany, S.Y., and Rafii, S. Expansion and maintenance of human vasculogenic embryonic stem cell-derived endothelial cells by TGF β inhibition is Id1 dependent. *Nat Biotechnol* **28**, 161, 2010.

Address correspondence to:
Sina Y. Rabbany, Ph.D.
Department of Genetic Medicine
Weill Cornell Medical College
1300 York Ave., Room A-863
510 E. 70th St.
New York, NY 10065

E-mail: sir2007@med.cornell.edu

Received: March 24, 2010

Accepted: March 31, 2010

Online Publication Date: April 29, 2010